In the pharmaceutical industry, firms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps firms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug...

Abstract: Despite the fact that one of the main goals of corporate venture capital (CVC) investments in high-tech industries is to gain a window on future technologies, the relationship between CVC investments and strategies used to acquire technologies in the markets, such as licensing, has not...

International new ventures (INVs) have been documented to exist all around the world, but the literature is silent on the frequency of such companies in different countries. We contend that the propensity of new ventures to internationalize by forming international partnerships is higher in...

There are several determinants that could have an effect on in-licensing decisions by a pharmaceutical or biotech firm. This work studies over 200 licensing deals involving big pharma companies in the period (2011 – 2015) and identifies different factors that could play a role in licensing...

Today a plethora of inter-company alliances exists. Firms have networked value chains, disclosing consequently their strategy, which assets are internalized or externalized, and their ability to cope with fast change. The picture of all interfirm alliances in high tech sectors is that of an...

This paper focuses on the clustering dynamics based on/supported by R&D offshoring trends as exemplified by the biopharmaceutical sector in China. It suggests two baselines of the institutional arrangements appropriate to initiate innovation-based clusters: (1) emphasis on the linkages and...

Au-delà de ses fonctions en termes de protection et de financement de l’innovation, le brevet est aussi un instrument de médiation et un support d’interactions. Dans le cas du développement des nouveaux vaccins issus du génie génétique, nous montrons qu’il est une composante...

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

Die vorliegende Studie wurde im Auftrag des Bundesministeriums für Wirtschaft und Technologie erstellt und im Oktober 2006 abgeschlossen. Gegenstand der Studie ist die Untersuchung des Globalisierungs- und Anpassungsprozesses sowie seiner Ergebnisse in Deutschland, Frankreich, Großbritannien,...

We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competitors in R&D and product markets. The data collected comprises 329 license-outs and 434 license-ins closed by 54 Japanese pharmaceutical companies between 1997 and 2007....